Susceptibility of β-Lactam Antibiotics and Genetic Mutation of Drug-Resistant Mycobacterium tuberculosis Isolates in Korea

Sanghee Park, Ph.D.1, Jihee Jung, M.Sc.1, Jiyeon Kim, M.Sc.1, Sang Bong Han, M.D.2 and Sungweon Ryoo, Ph.D.1
1Clinical Research Center, Masan National Tuberculosis Hospital, Changwon, 2Department of Laboratory Medicine, Masan National Tuberculosis Hospital, Changwon, Republic of Korea

Abstract

Background: Mycobacterium tuberculosis (Mtb) is resistant to the β-lactam antibiotics due to a non-classical transpeptidase in the cell wall with β-lactamase activity. A recent study showed that meropenem combined with clavulanate, a β-lactamase inhibitor, was effective in multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). However, in Korea, clavulanate can only be used as drugs containing amoxicillin. In this study, we investigated the susceptibility and genetic mutations of drug-resistant Mtb isolates to amoxicillin-clavulanate and meropenem-clavulanate to improve the diagnosis and treatment of drug-resistant TB patients.

Methods: The minimum inhibitory concentration (MIC) of amoxicillin-clavulanate and meropenem-clavulanate was examined by resazurin microtiter assay. We used 82 MDR and 40 XDR strains isolated in Korea and two reference laboratory strains. Mutations of drug targets blaC, blaI, ldta, ldTB, dacB2, and crfA were analyzed by polymerase chain reaction and DNA sequencing.

Results: The MIC90 values of amoxicillin/clavulanate and meropenem/clavulanate in drug-resistant Mtb isolates were 64/2.5 and 16/2.5 mg/L, respectively. Gene mutations related to amoxicillin/clavulanate and meropenem/clavulanate resistance could not be identified, but T448G mutation was found in the blaC gene related to β-lactam antibiotics’ high susceptibility.

Conclusion: Our results provide clinical consideration of β-lactams in treating drug-resistant TB and potential molecular markers of amoxicillin-clavulanate and meropenem-clavulanate susceptibility.

Keywords: Susceptibility; Amoxicillin; Clavulanate; Meropenem; Mutation; Resistance; Multidrug-Resistant; Extensively Drug-Resistant; Mycobacterium; Tuberculosis

Introduction

Emergence of multi-drug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) is a public health problem of TB. Treatment of MDR-TB requires a more extended treatment period, higher cost, and more drug adverse events than drug-sensitive TB1. Of the two, XDR-TB is more difficult to treat and has a relatively high mortality rate than MDR-TB2.

The β-lactamase of Mycobacterium tuberculosis
(Mtb) rapidly hydrolyzes β-lactam rings in amoxicillin and carbapenem and therefore they are combined with clavulanate, a β-lactam inhibitor, to exert anti-tuberculosis effects. Among the β-lactam antibiotics, meropenem, a carbapenem, in combination with clavulanate showed promising results in treating drug-resistant TB with low rates of adverse events. However, in Korea, clavulanate can only be used as drugs containing amoxicillin.

A critical concentration and breakpoint for amoxicillin/clavulanate and meropenem/clavulanate susceptibility testing for Mtb have not been defined by the World Health Organization (WHO), the Clinical & Laboratory Standards Institute (Wayne, PA, USA), and European Committee on Antimicrobial Susceptibility Testing (EUCAST). However, amoxicillin/clavulanate and meropenem/clavulanate have not been tested for drug susceptibility before being prescribed to patients with MDR and XDR-TB in Korea. Consequently, there is no information on the susceptibility distribution of amoxicillin/clavulanate and meropenem/clavulanate against MDR and XDR-TB isolates in Korea.

In this study, we investigated the susceptibility and genetic mutations of drug-resistant Mtb isolates to amoxicillin/clavulanate and meropenem/clavulanate to improve the diagnosis and treatment of drug-resistant TB patients.

Materials and Methods

1. Reference strains and clinical isolates of Mtb

The Mtb H37Rv (ATCC 25618) and K-strain (NCCP 15986) were used as references in the drug susceptibility test. The 82 MDR, and 40 XDR isolates were supplied by the Tuberculosis Specimen Bank of Masan National Hospital. The clinical isolates were collected from November 2009 to January 2016. The isolates used in this study did not have drug susceptibility test results for bedaquiline or linezolid, so the definition of XDR before 2021 was used for drug resistance criteria. The MDR was defined as resistant to both isoniazid and rifampin. The XDR was defined as MDR plus resistance to any fluoroquinolone and any second-line injectable drug (capreomycin, kanamycin, and amikacin). The clinical isolates of Mtb, Middlebrook 7H9 Broth (BBL MGIT Mycobacteria Growth Indicator Tube, Becton-Dickinson, Sparks, MD, USA), and Ogawa II agar (Asanpharm, Seoul, Korea) were sequentially cultured and used. The bacterial colonies in the log phase were taken and applied to determine the minimum inhibitory concentration (MIC), polymerase chain reaction (PCR), and DNA sequencing.

2. Determination of MIC

The MIC of the TB strains was measured using the resazurin microtiter assay. Amoxicillin and meropenem (Sigma-Aldrich, St. Louis, MO, USA) were added to 7H9-S broth with final concentrations ranging from 0.031 to 128 mg/L in 96-well plates. Potassium clavulanate (Sigma-Aldrich) was added to 7H9-S broth with a final concentration of 2.5 mg/L in each well. Growth controls containing no antibiotic and sterility controls without inoculation were also included. The inoculum was adjusted to McFarland 1.0 with DensiCHEK plus instrument (bioMereux, Craponne, France) from fresh colonies on Ogawa II agar, and further diluted at a ratio of 1:10 in 7H9-S broth. The MIC was determined as the lowest concentration where no color change occurred by culturing Mtb in 7H9-S broth containing various concentrations of Amoxicillin and meropenem for up to 9 days, then adding resazurin (Fisher Scientific, Waltham, MA, USA) and culturing for up to 48 hours. The Mtb H37Rv (ATCC 25618) and Mtb K-strain (NCCP 15986) were used as references in the drug susceptibility test. Drug susceptibility tests for the isolates that showed MIC >32/2.5 mg/L in to amoxicillin/clavulanate or meropenem/clavulanate, were repeated twice.

3. PCR and DNA sequencing

Mtb DNA was extracted using a commercial kit, DNeasy UltraClean Microbial Kit (Qiagen, Hilden, Germany) for PCR of the β-lactam resistance and susceptibility-related genes. PCR amplification of the genes was performed using Maxime PCR premix i-StarTaq (iNtRON, Seongnam, Korea). To identify genes related to high amoxicillin and meropenem susceptibility, seven strains with MIC ≤2 mg/L were selected, and DNA was extracted. Five strains with amoxicillin MIC >32 mg/L or meropenem MIC >16 mg/L were selected, and DNA was extracted to identify genes related to high β-lactam antibiotics resistance. Drug resistance data of the clinical Mtb isolates selected for PCR, and DNA sequencing are shown in Table 1.

The blaC, blaI, ldtA, ldtB, dacB2, and crfA genes were amplified by PCR. Genomic DNA from Mtb isolates and reference strains were subjected to PCR amplification. The primer sets for amplification and sequencing of the β-lactam resistance and susceptibility-related genes are shown in Table 2. The PCR amplification products of each gene were performed using Sanger sequencing with the same primers by Bioneer (Daejeon, Korea). To confirm the mutation site of the genes, each Mtb strain was compared and analyzed using Mega 10.2.5 software.
4. Statistical analysis

The susceptibility rates of Mtb isolates to amoxicillin and meropenem with clavulanate were analyzed using the Chi-square test. A cross-tabulation analysis was used to assess meropenem and amoxicillin susceptibility between MDR and XDR isolates. We used the nonparametric test because the MICs were recorded as discrete ordinal values and were not continuous. Fisher’s exact test and Paired sample t-test were used to compare the susceptible rates of MDR and XDR isolates to meropenem and amoxicillin with clavulanate. A p-value of <0.05 was considered statistically significant.

| Isolates No. | Type | Drug resistance profile | Year of isolation | MIC (mg/L) with 2.5 mg/L clavulanate |
|--------------|------|-------------------------|-------------------|-------------------------------------|
|              |      |                         |                   | Amoxicillin | Meropenem |
| 21873        | MDR  | INH, RFP, EMB, RBU, PTO | 2014              | 1          | 1         |
| 22549        | MDR  | INH, RFP, RBU, OFX, LEV, MFX, PTO, CS | 2015 | 2 | 2 |
| 25046        | MDR  | INH, RFP, EMB, RBU, SM, OFX, LEV, MFX, PAS, PTO, CS | 2015 | 2 | 2 |
| 6631         | XDR  | INH, RFP, EMB, RBU, SM, KM, AMK, OFX, PAS, PTO, CS | 2010 | 2 | 2 |
| 8002         | XDR  | INH, RFP, EMB, RBU, SM, KM, AMK, OFX, PAS, PTO, CS | 2010 | 2 | 2 |
| 13673        | XDR  | INH, RFP, EMB, RBU, SM, KM, OFX, MFX, PTO | 2011 | 1 | 1 |
| 16081        | XDR  | INH, RFP, RBU, SM, KM, AMK, OFX, PAS, PTO, CS | 2012 | 2 | 2 |
| 22009        | MDR  | INH, RFP, EMB, SM, PAS, PTO, CS | 2014 | 128 | 64 |
| 23920        | MDR  | INH, RFP, EMB, RBU, KM, PAS, PTO, CS | 2015 | 64 | 32 |
| 24605        | MDR  | INH, RFP, EMB, PTO | 2015 | 128 | 64 |
| 24649        | MDR  | INH, RFP, EMB, PTO | 2015 | 128 | 64 |
| 23425        | XDR  | INH, RFP, EMB, PZA, KM, AMK, CPM, OFX, PAS, PTO, CS | 2015 | >128 | 32 |

Mtb: Mycobacterium tuberculosis; MIC: minimum inhibitory concentration; MDR: multidrug-resistant; INH: isoniazid; RFP: rifampicin; EMB: ethambutol; RBU: rifabutin; PTO; protionamide; OFX: ofloxacin; LEV: levofloxacin; MFX: moxifloxacin; CS: cycloserine; SM: streptomycin; XDR: extensively drug-resistant; KM: kanamycin; AMK: amikacin; PAS: para-aminosalicylic acid; PZA: pyrazinamide; CPM: capreomycin.

| Primer | Sequence (5'-3') | Product length (bp) | Reference |
|--------|-----------------|---------------------|-----------|
| BlaCF  | ATGCAGCAACAGAGGATTCCGTC | 924 | Li et al. 
| BlaCR  | CTATGCAAGCACACCGCAACG | 457 |
| crfAF  | ACCCGGCTCACAGAGAATCG | 1,196 |
| crfAR  | TATCGCGGTAGGCCATGC | 756 |
| dacB2F | ACCAGCAACTGCTGATTTC | 1,227 |
| dacB2R | GTGTGATGACCAACGGTTTC | 2,277 |
| LdtBF  | ATGCAGCAAGGTGGGATTGC | 475 |
| LdtBR  | TTACGCTTTGGGCTTTCCG | 756 |
| LdtAF  | ATGCAGCAAGGTGGGATTGC | 1,227 |
| LdtAR  | CTAGCCGACACCTGTAATGC | 417 |
| BlaIF  | ATGGCAGCAAGGTGGGATTGC | In this study |
| BlaIR  | TCAAGTCTCCGTTCCG | 1,227 |

Table 1. Drug resistance data of clinical Mtb isolates to identify genes related to resistance and susceptibility to β-lactam antibiotics

Table 2. Primers used for amplification and sequencing of the β-lactam resistance and susceptibility-related genes
5. Ethics
This study protocol was approved by the Institutional Biosafety Committee (MTHIBC-18-11) and Institutional Review Board (IRB-398837-2018-E-26) of the Masan National Tuberculosis Hospital. The clinical information was retrieved by the medical staff from electronic medical records, to analyze the relationship between the treatment history and progress in patients with β-lactam resistance.

Results
1. MIC to Mtb
Amoxicillin/clavulanate MIC values of H37Rv were from 32 to 64/2.5 mg/L, and K-strain was from 64 to 128/2.5 mg/L. Meropenem/clavulanate MIC values of H37Rv were from 8 to 16/2.5 mg/L, and K-strain was from 16 to 64/2.5 mg/L. The WHO does not define a critical concentration and breakpoint for amoxicillin/clavulanate and meropenem/clavulanate susceptibility testing for Mtb. Based on a previously described study, the tentative susceptible criterion of amoxicillin/clavulanate and meropenem/clavulanate was ≤4/2.5 mg/L and ≤8/2.5 mg/L, respectively. The susceptibilities of drug-resistant isolates to different concentrations of amoxicillin and meropenem with clavulanate are shown in Table 3. Clinical Mtb isolates to 4 mg amoxicillin and 8 mg meropenem with potassium clavulanate at 2.5 mg/L, showed 24.6% (30/122) and 94.3% (115/122), respectively. Among these, MDR and XDR strains were 28.0% (23/82) and 17.5% (7/40) susceptible to amoxicillin-clavulanate, respectively. The susceptibility rates of clinical Mtb isolates were increased on two additional concentrations of amoxicillin and meropenem. MDR and XDR strains were 85.4% (70/82) and 87.5% (35/40) susceptible to meropenem-clavulanate, respectively. The amoxicillin-clavulanate susceptibilities were higher in MDR than XDR, but the difference was not statistically significant (p=0.38). The meropenem-clavulanate susceptibilities were higher in XDR than MDR, but the difference was not statistically significant (p=0.12). The MICs of the amoxicillin and meropenem with clavulanate for MDR and XDR Mtb isolates are shown in Figure 1. M_{50} and M_{90} values of amoxicillin/clavulanate, which mean 50% and more than 90% inhibition of the target Mtb, were 16/2.5 mg/L and 64/2.5 mg/L, respectively. The M_{50} and M_{90} values of meropenem/clavulanate were 8/2.5 mg/L and 16/2.5 mg/L, respectively. The M_{50} and M_{90} values of amoxicillin/clavulanate were higher than those of the meropenem/clavulanate (p=0.001). XDR-TB is more difficult to treat than MDR-TB. Therefore, we included XDR Mtb, since in vitro susceptibility to amoxicillin/clavulanate and meropenem/clavulanate may provide effective treatment options for patients with XDR-TB. The M_{50} and M_{90} values of amoxicillin/clavulanate, which mean 50% and more than 90% inhibition of the target Mtb, for MDR were 8/2.5 mg/L and 64/2.5 mg/L, respectively. The M_{50} and M_{90} values of meropenem/clavulanate for MDR were 4/2.5 mg/L and 16/2.5 mg/L, respectively. The M_{50} values of amoxicillin/clavulanate were higher in XDR than MDR (p<0.001), and the M_{90} values of amoxicillin/clavulanate were higher in MDR than XDR (p<0.001). The M_{50} and M_{90} values of meropenem/clavulanate for MDR were 4/2.5 mg/L and 16/2.5 mg/L, respectively. The M_{50} and M_{90} values of meropenem/clavulanate for XDR were 8/2.5 mg/L and 16/2.5 mg/L, respectively.

Table 3. Susceptibilities of MDR and XDR-TB isolates to different concentrations of amoxicillin and meropenem with clavulanate (2.5 mg/mL)

| Critical concentration (mg/L) | MDR (n=82) | XDR (n=40) | Total (n=122) |
|-----------------------------|------------|------------|--------------|
| **Amoxicillin**             |            |            |              |
| 4.0                         | 23 (28.0)  | 7 (17.5)   | 30 (24.6)    |
| 8.0                         | 42 (51.2)  | 18 (45.0)  | 60 (49.2)    |
| 16.0                        | 61 (74.4)  | 28 (70.0)  | 89 (73.0)    |
| **Meropenem**               |            |            |              |
| 4.0                         | 32 (39.0)  | 22 (55.0)  | 54 (44.3)    |
| 8.0                         | 70 (85.4)  | 35 (87.5)  | 115 (94.3)   |
| 16.0                        | 78 (95.1)  | 39 (97.5)  | 117 (96.0)   |

Values are presented as number (%).
MDR: multidrug-resistant; XDR: extensively drug-resistant; TB: tuberculosis.
for XDR were 8/2.5 mg/L and 16/2.5 mg/L, respectively. The MIC<sub>50</sub> values of meropenem/clavulanate were higher in XDR than MDR (p<0.001).

2. Clinical data analysis of β-lactam resistant isolates
The treatment history of the patients and bacterial culture test of isolates are shown in Table 4. The five strains confirmed to be highly resistant to amoxicillin MIC >32 mg/L or meropenem MIC >16 mg/L, were isolated from four patients. Only a patient from whom 23920 strain was isolated, had a history of treatment with amoxicillin-clavulanate for 12 months during inpatient treatment. However, the isolate was cultured from the patient before administering amoxicillin-clavulanate and meropenem. The other patients had no history of treatment with amoxicillin-clavulanate and meropenem. The relationship between drug discontinuation and resistance was low in the β-lactam resistant isolates.

3. Relationship between drug target mutation and resistance and susceptibility
The relationship between mutations in the β-lactam target genes and the drug susceptibility and resistance was investigated. A total of 12 Mtb isolates with blaC, blal, crfa, ldta, ldTB, and dacB2 genes were sequenced and analyzed. Gene mutations related to amoxicillin and meropenem resistance could not be identified in five resistant Mtb isolates.

The G514A a sensitivity-related mutation in the blaC gene previously reported concerning β-lactam drug-susceptibility<sup>11</sup>, could not identify the same positional mutation in the seven susceptible Mtb isolates. However, the T448G common mutation of the blaC gene was identified in susceptible Mtb isolates, as shown in Figure 2. The T448G mutation of the blaC was observed in four isolates among the seven β-lactam susceptible Mtb isolates. The mutation was detected with a higher frequency in XDR than in MDR among the β-lactam drug-susceptible Mtb isolates.
Figure 2. The blaC gene mutation site in β-lactam susceptible and resistant isolates. The mutation site of single nucleotide variants is shown with white arrows and squares. MDR: multidrug-resistant; XDR: extensively drug-resistant.

Discussion

In our results, amoxicillin-clavulanate and meropenem-clavulanate of H37Rv were 2 to 4 times higher than those of each drug compared to previous research reports. The clavulanate concentration of the previous MIC investing studies ranged from 2.5 mg to 10 mg. As the clavulanate concentration increased, the MICs of amoxicillin and meropenem gradually decreased using the H37Rv strain. This difference in the reference strains’ MIC of amoxicillin-clavulanate and meropenem-clavulanate could be due to the difference in susceptibility test methods and characteristics of the reference strains. Therefore, the drug susceptibility test should be standardized.

Amoxicillin-clavulanate showed variable effectiveness against Mtb in the previous susceptibility studies. The Cmax and AUC values of amoxicillin were 11.2 mg/L and 30.1 mg hr/L, respectively, after a single oral dose of 1,000 mg of AUGMENTIN, an amoxicillin-clavulanate combination. The Cmax and AUC values of clavulanate in serum were 2.6 mg/L and 4.6 mg hr/L, respectively, after a single oral dose of 1,000 mg of AUGMENTIN. Our data, documenting an MIC of 32 mg/L of amoxicillin, suggests that this dosage of amoxicillin-clavulanate will not be effective against drug-resistant TB.

Meropenem has shown good efficacy against drug-resistant isolates of Mtb in the previous studies. Meropenem with clavulanate exhibited anti-Mtb activity with MIC of 2 mg/L and 8 mg/L, respectively. The Cmax and AUC values of meropenem were 26 mg/L and 27.2–32.4 mg hr/L, respectively, with an intravenous infusion of 500 mg of meropenem. Our meropenem-clavulanate results with an MIC of 16 mg/L are comparable to previous investigations which showed potent activity against drug-resistant Mtb.

The drug-resistant Mtb were 58% and 94% susceptible to amoxicillin-clavulanate and meropenem-clavulanate, respectively. A specific clade LAM4 type of XDR strains from South Africa exhibited high susceptibility to certain β-lactam antibiotics. The resistance criterion of amoxicillin and meropenem with clavulanate (2.5 mg/L) was MIC >4 mg/L and MIC >12 mg/L, respectively. Our drug susceptibility rate data of amoxicillin-clavulanate and meropenem-clavulanate, as in the same resistance criteria, were 60/122 (49.2%) and 115/122 (94.3%), respectively. The lower susceptibility rates of amoxicillin could be due to the different clade types from other areas, so it is necessary to conduct a drug susceptibility test before treating drug-resistant patients in Korea with β-lactam antibiotics.

The relationship between drug discontinuation and resistance was low in this study. The cause of the resistance was not related to treatment with amoxicillin and meropenem. It is expected that the main mechanism of acquired resistance to drugs such as amoxicillin and meropenem is infection by bacteria that have already developed drug resistance rather than acquiring resistance to Mtb through discontinuation of related medications. It is necessary to analyze a higher number of drug-resistant Mtb and the gene that changes during drug treatment, for more accurate results.

The study on the mechanism of Mtb resistance to β-lactam antibiotic-clavulanate focused on β-lactamases expressed by blaC gene. Structural changes of β-lactamases due to gene mutation may cause drug resistance by interfering with the action of clavulanate, a β-lactamase inhibitor. Through structural analysis of the β-lactamase proteome, N132, R164, R244, S130, and T237 sites were predicted to be related to drug resistance. It was reported that the mutation sites of the blaC gene T333G and G514A are related to sensitivity rather than resistance. The β-lactam antibiotics inhibit cell wall synthesis by binding to transpeptidases that catalyze peptidoglycan cross-linking. An alternative form of peptidoglycan cross-linking, called L,D-transpeptidation, is predominant in Mtb. The transpeptidase encoding related genes, ldtA, ldtB, dacB2, crfA, and bial were analyzed to determine the relationship between drug target mutations and β-lactam resistance and susceptibility. We could not observe the exact position of these gene mutations of previous studies in the β-lactam resistance and susceptibility isolates in this study. However, common mutations of the blaC gene T448G were observed in β-lactam high susceptible isolates. The mutation T448G may affect the interaction of blaC and β-lactams.
and the amino change Leu150Val leads to a conformation change in blaC, which influences its activity. The T448G mutation was detected with a higher frequency in XDR than in MDR among the β-lactam drug-susceptible Mtb isolates. This is considered to have important clinical implications on the treatment of XDR TB, limited to the drug of choice. Furthermore, it is expected that the gene mutations related to drug susceptibility, such as β-lactam antibiotics, revealed through this study can be used as a marker for rapid diagnosis of TB drug susceptibility in the future.

Authors’ Contributions

Conceptualization: Park S. Methodology: Jung J, Park S. Formal analysis: Kim J, Han SB, Park S. Writing - original draft preparation: Park S, Ryoo S. Writing - review and editing: Park S, Ryoo S. Approval of final manuscript: all authors.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

We thank the staff and researchers of the clinical research center and department of laboratory medicine of Masan National Tuberculosis Hospital.

Funding

This study was supported by an intramural grant (4631-304-210-13) from Masan National Tuberculosis Hospital, Korea.

References

1. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009;9:153-61.
2. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010;51:6-14.
3. Sotgiu G, D’Ambrosio L, Centis R, Tiberi S, Esposito S, Dore S, et al. Carbapenems to treat multidrug and extensively drug-resistant tuberculosis: a systematic review. Int J Mol Sci 2016;17:373.
4. Tiberi S, Payen MC, Sotgiu G, D’Ambrosio L, Alarcon Guizado V, Alffenaar JW, et al. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Eur Respir J 2016;47:1235-43.
5. World Health Organization. Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis [Internet]. Geneva: World Health Organization; 2018 [cited 2022 Jan 10]. Available from: https://www.who.int/publications/i/item/WHO-CDS-TB-2018.5.
6. Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, Nocardiae, and other aerobic actinomycetes. Report No. M24-A2. 2nd ed. Wayne: Clinical and Laboratory Standards Institute; 2011.
7. European Committee on Antimicrobial Susceptibility Testing. EUCAST 2022 Clinical breakpoints and dosing of antibiotics [Internet]. Basel: European Society of Clinical Microbiology and Infectious Disease; 2022 [cited 2022 Jan 10]. Available from: https://www.eucast.org/clinical_breakpoints/.
8. Centers for Disease Control and Prevention. Revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 2006;55:1176.
9. Martin A, Camacho M, Portaels F, Palomino JC. Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method. Antimicrob Agents Chemother 2003;47:3616-9.
10. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol 2018;35:1547-9.
11. Li F, Wan L, Xiao T, Liu H, Jiang Y, Zhao X, et al. In vitro activity of beta-lactams in combination with beta-lactamase inhibitors against Mycobacterium tuberculosis clinical isolates. Biomed Res Int 2018;2018:3579832.
12. Cohen KA, El-Hay T, Wyres KL, Weissbrod O, Munsamy V, Yanover C, et al. Paradoxical hypersusceptibility of drug-resistant Mycobacterium tuberculosis to beta-lactam antibiotics. EBioMedicine 2016;9:170-9.
13. Cavanaugh JS, Jou R, Wu MH, Dalton T, Kurbatova E, Ershova J, et al. Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters. J Antimicrob Chemother 2017;72:1678-87.
14. Fraschini F, Scaglione F, Falchi M, Dugnani S, Mezzetti M, Cicchetti F, et al. Pharmacokinetics and tissue distribution of amoxicillin plus clavulanic acid after oral administration in man. J Chemother 1990;2:171-7.
15. Davies Forsman L, Giske CG, Bruchfeld J, Schon T, Juureen P, Angeby K. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis. Int J Mycobacteriol 2015;4 Suppl 1:80-1.
16. Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis 2008;47 Suppl 1:S32-40.
17. Wang F, Cassidy C, Sacchettini JC. Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics. Antimicrob Agents Chemother 2006;50:2762-71.
18. Kurz SG, Wolff KA, Hazra S, Bethel CR, Hujer AM, Smith KM, et al. Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis beta-Lactamase BlaC lead to clavulanate resistance?: a biochemical rationale for the use of beta-lactam-beta-lactamase inhibitor combinations. Antimicrob Agents Chemother 2013;57:6085-96.
19. Zhang D, Wang Y, Lu J, Pang Y. In vitro activity of beta-lactams in combination with beta-lactamase inhibitors against multidrug-resistant Mycobacterium tuberculosis Isolates. Antimicrob Agents Chemother 2016;60:393-9.
20. Dubee V, Triboulet S, Mainardi JL, Etheve-Quelquejeu M, Gutmann L, Marie A, et al. Inactivation of Mycobacterium tuberculosis L,d-transpeptidase LdtMt(1) by carbapenems and cephalosporins. Antimicrob Agents Chemother 2012;56:4189-95.